A W McMahon

Summary

Affiliation: Food and Drug Administration
Country: USA

Publications

  1. ncbi Description of hypersensitivity adverse events following administration of heparin that was potentially contaminated with oversulfated chondroitin sulfate in early 2008
    Ann W McMahon
    Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20993, USA
    Pharmacoepidemiol Drug Saf 19:921-33. 2010
  2. ncbi Comparison of military and civilian reporting rates for smallpox vaccine adverse events
    A W McMahon
    Office of Biostatistics and Epidemiology, Food and Drug Administration, Rockville, MD, USA
    Pharmacoepidemiol Drug Saf 16:597-604. 2007
  3. ncbi Inactivated influenza vaccine (IIV) in children <2 years of age: examination of selected adverse events reported to the Vaccine Adverse Event Reporting System (VAERS) after thimerosal-free or thimerosal-containing vaccine
    A W McMahon
    Office of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research, Food and Drug Administration, USA
    Vaccine 26:427-9. 2008
  4. ncbi Age and risks of FDA-approved long-acting β₂-adrenergic receptor agonists
    Ann W McMahon
    Office of Pediatric Therapeutics, Office of the Commissioner, Food and Drug Administration, Silver Spring, MD 20993, USA
    Pediatrics 128:e1147-54. 2011
  5. ncbi Photophobia following smallpox vaccination
    A W McMahon
    Vaccine 23:1097-8. 2005

Detail Information

Publications5

  1. ncbi Description of hypersensitivity adverse events following administration of heparin that was potentially contaminated with oversulfated chondroitin sulfate in early 2008
    Ann W McMahon
    Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20993, USA
    Pharmacoepidemiol Drug Saf 19:921-33. 2010
    ..The investigation identified Baxter Healthcare-brand heparin product due to its strongest association with the events. Later, oversulfated chondroitin sulfate (OSCS), a heparin-like contaminant, was discovered...
  2. ncbi Comparison of military and civilian reporting rates for smallpox vaccine adverse events
    A W McMahon
    Office of Biostatistics and Epidemiology, Food and Drug Administration, Rockville, MD, USA
    Pharmacoepidemiol Drug Saf 16:597-604. 2007
    ....
  3. ncbi Inactivated influenza vaccine (IIV) in children <2 years of age: examination of selected adverse events reported to the Vaccine Adverse Event Reporting System (VAERS) after thimerosal-free or thimerosal-containing vaccine
    A W McMahon
    Office of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research, Food and Drug Administration, USA
    Vaccine 26:427-9. 2008
    ....
  4. ncbi Age and risks of FDA-approved long-acting β₂-adrenergic receptor agonists
    Ann W McMahon
    Office of Pediatric Therapeutics, Office of the Commissioner, Food and Drug Administration, Silver Spring, MD 20993, USA
    Pediatrics 128:e1147-54. 2011
    ..To determine the risk, by age group, of serious asthma-related events with long-acting β(2)-adrenergic receptor agonists marketed in the United States for asthma...
  5. ncbi Photophobia following smallpox vaccination
    A W McMahon
    Vaccine 23:1097-8. 2005